Relief Therapeutics Holding AG (RLFTF)

[DonDonDonDon]

In the release by neurorx & relief therapeutics, the mean Hospital stay decreased by 11 days. Instead of 26 days, patients were discharged at day 15. You can read the release on relief therapeutics website. If you haven't read the release, then you should to learn the facts from the clinical trials.....

Among the secondary efficacy endpoints evaluated in patients treated with High Flow Nasal Cannula (HFNC) therapy and with Mechanical Ventilation, ZYESAMI showed an advantage in 15 of 16 comparisons and demonstrated a 40% or better advantage (hazard ratio <0.7). The likelihood of this magnitude of advantage being seen by chance alone is about 1 in 2,000 (P=.0005). This difference includes at least a five-day median reduction in hospital stay. (P=.043). The largest difference observed was among those treated with HFNC who experienced a median of 11 fewer days in hospital (15 vs. 26).
Dr. Javitt said: “The data provide preliminary support for ZYESAMI as a drug that may help get critically-ill patients home to their families sooner. The hospitalization data further suggest that patients treated at an earlier stage of illness (i.e., those who can be managed with HFNC) may have a better response to treatment. We have launched a phase 2/3 trial to explore ZYESAMI’s inhaled use in patients who are not yet in respiratory failure.